Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)
- Conditions
- Ulcerative Colitis
- Interventions
- Registration Number
- NCT01532648
- Lead Sponsor
- Bausch Health Americas, Inc.
- Brief Summary
This study is to compare the efficacy and safety of budesonide MMX 9 mg versus placebo as add-on therapy to an existing oral 5-ASA regimen for the induction of remission in participants with active mild or moderate ulcerative colitis (UC).
- Detailed Description
Eligible participants will be randomized to 1 of the following 2 treatment arms:
1. Budesonide MMX 9 mg (1 tablet)
2. Placebo (tablet indistinguishable from budesonide MMX 9 mg tablet)
The assigned study drug will be taken as a single oral tablet each morning after breakfast. In addition to the study drug, all participants will continue their existing background oral 5-ASA regimen during the treatment period.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 510
- Age 18 to 75 years, inclusive.
- Established diagnosis of UC, based on clinical history, exclusion of infectious causes, and characteristic endoscopic and histologic findings.
- Active mild or moderate UC with an ulcerative colitis disease activity index (UCDAI) score ≥4 and ≤10, with a mucosal appearance score of ≥1, and physician's rating of disease activity of 1 or 2.
- Experiencing active UC (flare) despite a therapeutic dose of an oral 5-ASA (for example, mesalamine ≥2.4 g/day for ≥6 weeks prior to randomization, or equivalent). At screening, photographic evidence of active UC based on mucosal appearance must be obtained.
- Women of childbearing potential or men of reproductive potential must be willing to use an acceptable form of contraception.
- Able to comprehend the full nature and purpose of the study, including possible risks and side effects, and also able to comply with all requirements of the study. Must be able to understand and voluntarily sign an informed consent prior to any study procedures.
- Limited distal proctitis (from anal verge to 15 centimeters [cm] above the pectineal line).
- Severe UC (UCDAI >10 or physician global assessment [PGA] >2), or non-active UC (UCDAI <4).
- Infectious colitis or any recent history of infectious colitis (within 30 days of Screening).
- Active malignancy or carcinoma in situ within the last 5 years (treated non-melanoma skin cancers are not exclusionary).
- Active ulcer or bleeding disorder that may affect evaluation of blood in the stool.
- Evidence or history of toxic megacolon or bowel resection.
- Crohn's disease or indeterminate colitis.
- Known hypersensitivity to budesonide or any ingredients of the budesonide MMX tablets.
- Active tuberculosis or other active systemic or local bacterial, fungal, or viral infection.
- Liver cirrhosis, evident hepatic or renal disease or insufficiency, or significant impairment of the biohumoral parameters (≥2.5*upper limit of normal [ULN] for alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transpeptidase, or ≥2*ULN for creatinine). Elevations in bilirubin due to benign conditions such as Gilbert's syndrome are not exclusionary.
- Severe diseases in other organs or systems.
- Local or systemic complications or other pathological states requiring therapy with corticosteroids and/or immunosuppressive agents.
- Type 1 diabetes.
- Glaucoma or with a family history of glaucoma in first-degree relatives.
- Known hepatitis B, hepatitis C, or human immunodeficiency virus (HIV), according to the local privacy policy.
- Severe anemia (<9 g/deciliter [dL] hemoglobin), leukopenia (<2.5*10^9 white blood cells [WBC]/liter [L]), or granulocytopenia (<1.2*10^9 cells/L).
- Participants with a history of pancolitis (disease that extends to the hepatic flexure or beyond) for ≥8 years or left-sided colitis (disease confined to the left colon [that is, distal to the splenic flexure]) ≥15 years who have not yet completed a surveillance colonoscopy for dysplasia/colorectal cancer screening within the past year.
- Prior budesonide MMX treatment.
- Use of oral corticosteroids including other budesonide formulations within the last 4 weeks prior to randomization.
- Use of any rectal 5-ASA or corticosteroid formulations within the last 2 weeks prior to randomization.
- Use of immunosuppressive agents within the last 8 weeks prior to randomization.
- Use of anti-tumor necrosis factor-alpha (TNFα) agents or other biologic therapies within the last 3 months prior to randomization.
- Participation in experimental therapeutic studies within 30 days of randomization (or within the last 3 months if in an anti-TNFα or biologic agent study). Note: participants who participated in observational-only studies (and who did not receive study therapy) are not excluded.
- Any other medical condition that, in the Principal Investigator's opinion, would make the administration of the study drug or study procedures hazardous to the participant or obscure the interpretation of adverse events (AEs) by the appropriate independent ethics committee/institutional review board.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Placebo Placebo Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician. Budesonide MMX Budesonide MMX® Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician. Budesonide MMX 5-ASA Participants will receive 1 oral tablet of budesonide MMX 9 mg for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician. Placebo 5-ASA Participants will receive 1 oral tablet of matching budesonide MMX placebo for 56 days. Additionally, participants will continue to receive the same dose of their existing oral 5-ASA medication from their treating physician.
- Primary Outcome Measures
Name Time Method Number of Participants Who Achieved Clinical Remission at Day 56 Baseline up to Day 56 Clinical remission defined as a score of 0 for rectal bleeding and 0 for stool frequency components from the Ulcerative Colitis Disease Activity Index (UCDAI). UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis. Participants who had clinical remission at Baseline were classified as non-responders.
- Secondary Outcome Measures
Name Time Method Number of Participants of Who Achieved Clinical Response at Day 56 Baseline up to Day 56 Clinical response defined as an improvement in UCDAI from Baseline of ≥3 points with a rectal bleeding score ≤1. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Rectal bleeding was based on information recorded in daily participant diaries. The diary entries were averaged for rectal bleeding for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If either subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.
Number of Participants Who Achieved Endoscopic Remission at Day 56 Screening and Day 56 Endoscopic remission was defined as a score of 0 in the mucosal appearance component subscore of the UCDAI at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Mucosal appearance was based on endoscopy results. If the mucosal appearance subscore could not be calculated because of missing data, endoscopic remission was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.
Number of Participants With Treatment Failure at Day 56 Baseline up to Day 56 Treatment failure was defined as an unchanged, worsened, or missing UCDAI score at Day 56. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding was based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.
Change From Baseline in Inflammatory Bowel Disease-Quality of Life (IBD-QoL) Questionnaire Scores Baseline, Days 14, 28, and 56 The IBD-QoL questionnaire was self-completed by the participant. The IBD-QoL is a disease-specific instrument to evaluate the quality of life of participants with UC. This 32-item questionnaire has 4 dimensions: bowel function, emotional function, systemic symptoms, and social function. The total score is presented, which ranges from 32 to 224, with higher scores indicating a better quality of life. The scores of participants in remission usually range from 170 to 190. If \>50% of the questionnaire answers for a particular dimension were missing, this dimension score was set to missing. The total score for the IBD-QoL was the sum of the domain scores, however, if any dimension score was missing, the total IBD-QoL score was set to missing.
Number of Participants Who Achieved UCDAI Remission at Day 56 Baseline up to Day 56 UCDAI remission was defined as a total UCDAI score ≤1 with subscores of 0 for rectal bleeding, stool frequency, and mucosal appearance of the colon. UCDAI is the sum (0 to 12) of 4 severity scores (0 to 3). Stool frequency and rectal bleeding were based on information recorded in daily participant diaries and mucosal appearance was based on endoscopy results. The diary entries were averaged for rectal bleeding and stool frequency for 3 days prior to (and closest to) Day 56 with non-missing diary data, within 5 days prior to (and closest to) Day 56. The 5 days did not include any days of the flexible sigmoidoscopy (or colonoscopy) or the preparation for the flexible sigmoidoscopy (or colonoscopy). These averages were rounded to integer values. If the subscore could not be calculated because of missing data, the score for that UCDAI component was set to missing. Participants with insufficient data at Day 56 were excluded from the analysis.
Number of Participants Who Achieved Histologic Healing at Day 56 Baseline and Day 56 Participants achieved histologic healing if histologic assessments of all biopsy specimens were graded as 0 (normal mucosa). If the score for ≥1 sample was missing, the overall score at that visit was set to missing. Participants with insufficient data at Day 56 were excluded from analysis.
Trial Locations
- Locations (114)
Santarus Clinical Investigational Site 9005
🇷🇺Moscow, Russian Federation
Santarus Clinical Investigational Site 4003
🇧🇬Pleven, Bulgaria
Santarus Clinical Investigational Site 4001
🇧🇬Sofia, Bulgaria
Santarus Clinical Investigational Site 8001
🇪🇪Tallinn, Estonia
Santarus Clinical Investigational Site 5001
🇭🇺Debrecen, Hungary
Santarus Clinical Investigational Site 9006
🇷🇺Ufa, Russian Federation
Santarus Clinical Investigational Site 4005
🇧🇬Sofia, Bulgaria
Santarus Clinical Investigational Site 4007
🇧🇬Sofia, Bulgaria
Santarus Clinical Investigational Site 4010
🇧🇬Sofia, Bulgaria
Santarus Clinical Investigational Site 8201
🇱🇹Vilnius, Lithuania
Santarus Clinical Investigational Site 6006
🇵🇱Szczecin, Poland
Santarus Clinical Investigational Site 9004
🇷🇺Nizhny Novgorod, Russian Federation
Santarus Clinical Investigational Site 7004
🇺🇦Kharkiv, Ukraine
Santarus Clinical Investigational Site 8101
🇱🇻Riga, Latvia
Santarus Clinical Investigational Site 5009
🇭🇺Budapest, Hungary
Santarus Clinical Investigational Site 8103
🇱🇻Riga, Latvia
Santarus Clinical Investigational Site 8203
🇱🇹Vilnius, Lithuania
Santarus Clinical Investigational Site 6002
🇵🇱Sopot, Poland
Santarus Clinical Investigational Site 6008
🇵🇱Warszawa, Poland
Santarus Clinical Investigational Site 5005
🇭🇺Szeged, Hungary
Santarus Clinical Investigational Site 5007
🇭🇺Vac, Hungary
Santarus Clinical Investigational Site 8202
🇱🇹Kaunas, Lithuania
Santarus Clinical Investigational Site 6003
🇵🇱Elblag, Poland
Santarus Clinical Investigational Site 6001
🇵🇱Krakow, Poland
Santarus Clinical Investigational Site 9016
🇷🇺Lipetsk, Russian Federation
Santarus Clinical Investigational Site 9010
🇷🇺Moscow, Russian Federation
Santarus Clinical Investigational Site 9003
🇷🇺Ryazan, Russian Federation
Santarus Clinical Investigational Site 7006
🇺🇦Kyiv, Ukraine
Santarus Clinical Investigational Site 7005
🇺🇦Vinnytsia, Ukraine
Santarus Clinical Investigational Site 6004
🇵🇱Warszawa, Poland
Santarus Clinical Investigational Site 6005
🇵🇱Warszawy, Poland
Santarus Clinical Investigational Site 9014
🇷🇺Saint Petersburg, Russian Federation
Santarus Clinical Investigational Site 9009
🇷🇺Saratov, Russian Federation
Santarus Clinical Investigational Site 9007
🇷🇺Stavropol, Russian Federation
Santarus Clinical Investigational Site 7010
🇺🇦Crimea, Ukraine
Santarus Clinical Investigational Site 1078
🇺🇸Cleveland, Ohio, United States
Santarus Clinical Investigational Site 1006
🇺🇸Sayre, Pennsylvania, United States
Santarus Clinical Investigational Site 1065
🇺🇸Oak Lawn, Illinois, United States
Santarus Clinical Investigational Site 1081
🇺🇸Novi, Michigan, United States
Santarus Clinical Investigational Site 1072
🇺🇸Great Neck, New York, United States
Santarus Clinical Investigational Site 1043
🇺🇸Anaheim, California, United States
Santarus Clinical Investigational Site 1063
🇺🇸Littleton, Colorado, United States
Santarus Clinical Investigational Site 1050
🇺🇸Decatur, Georgia, United States
Santarus Clinical Investigational Site 1061
🇺🇸Lebanon, New Hampshire, United States
Santarus Clinical Investigational Site 1010
🇺🇸Winter Park, Florida, United States
Santarus Clinical Investigational Site 1075
🇺🇸Chicago, Illinois, United States
Santarus Clinical Investigational Site 1016
🇺🇸Chesterfield, Michigan, United States
Santarus Clinical Investigational Site 1071
🇺🇸Lakewood, California, United States
Santarus Clinical Investigational Site 1045
🇺🇸Jacksonville, Florida, United States
Santarus Clinical Investigational Site 1035
🇺🇸Boynton Beach, Florida, United States
Santarus Clinical Investigational Site 1029
🇺🇸Port Orange, Florida, United States
Santarus Clinical Investigational Site 1001
🇺🇸Largo, Florida, United States
Santarus Clinical Investigational Site 1032
🇺🇸Shreveport, Louisiana, United States
Santarus Clinical Investigational Site 2002
🇨🇦Vaughan, Ontario, Canada
Santarus Clinical Investigational Site 1044
🇺🇸Annapolis, Maryland, United States
Santarus Clinical Investigational Site 2005
🇨🇦London, Canada
Santarus Clinical Investigational Site 1015
🇺🇸Wyoming, Michigan, United States
Santarus Clinical Investigational Site 3005
🇨🇿Labem, Czechia
Santarus Clinical Investigational Site 4009
🇧🇬Plovdiv, Bulgaria
Santarus Clinical Investigational Site 5003
🇭🇺Gyula, Hungary
Santarus Clinical Investigational Site 3001
🇨🇿Hradec Kralove, Czechia
Santarus Clinical Investigational Site 3004
🇨🇿Praha, Czechia
Santarus Clinical Investigational Site 2006
🇨🇦Quebec, Canada
Santarus Clinical Investigational Site 2010
🇨🇦Ottawa, Ontario, Canada
Santarus Clinical Investigational Site 2004
🇨🇦London, Ontario, Canada
Santarus Clinical Investigational Site 5008
🇭🇺Budapest, Hungary
Santarus Clinical Investigational Site 5010
🇭🇺Bekescsaba, Hungary
Santarus Clinical Investigational Site 5002
🇭🇺Miskolc, Hungary
Santarus Clinical Investigational Site 5011
🇭🇺Pecs, Hungary
Santarus Clinical Investigational Site 2007
🇨🇦Calgary, Canada
Santarus Clinical Investigational Site 4002
🇧🇬Sofia, Bulgaria
Santarus Clinical Investigational Site 4011
🇧🇬Sofia, Bulgaria
Santarus Clinical Investigational Site 3002
🇨🇿Tabor, Czechia
Santarus Clinical Investigational Site 3010
🇨🇿Usti nad Orlici, Czechia
Santarus Clinical Investigational Site 5004
🇭🇺Kaposvar, Hungary
Santarus Clinical Investigational Site 5006
🇭🇺Mosonmagyarovar, Hungary
Santarus Clinical Investigational Site 8102
🇱🇻Riga, Latvia
Santarus Clinical Investigational Site 3006
🇨🇿Hradec Kralove, Czechia
Santarus Clinical Investigational Site 3009
🇨🇿Prague, Czechia
Santarus Clinical Investigational Site 3003
🇨🇿Olomouc, Czechia
Santarus Clinical Investigational Site 3007
🇨🇿Praha, Czechia
Santarus Clinical Investigational Site 9013
🇷🇺Saint Petersburg, Russian Federation
Santarus Clinical Investigational Site 9001
🇷🇺St Petersburg, Russian Federation
Santarus Clinical Investigational Site 7002
🇺🇦Donetsk, Ukraine
Santarus Clinical Investigational Site 7001
🇺🇦Kharkiv, Ukraine
Santarus Clinical Investigational Site 7008
🇺🇦Kyiv, Ukraine
Santarus Clinical Investigational Site 2003
🇨🇦Winnipeg, Manitoba, Canada
Santarus Clinical Investigational Site 1058
🇺🇸Indianapolis, Indiana, United States
Santarus Clinical Investigational Site 1074
🇺🇸Rochester, Minnesota, United States
Santarus Clinical Investigational Site 3011
🇨🇿Valasske Mezirici, Czechia
Santarus Clinical Investigational Site 1068
🇺🇸Ypsilanti, Michigan, United States
Santarus Clinical Investigational Site 1082
🇺🇸Dayton, Ohio, United States
Santarus Clinical Investigational Site 1038
🇺🇸Chesapeake, Virginia, United States
Santarus Clinical Investigational Site 1059
🇺🇸Austin, Texas, United States
Santarus Clinical Investigational Site 1003
🇺🇸San Diego, California, United States
Santarus Clinical Investigational Site 1002
🇺🇸Zephyrhills, Florida, United States
Santarus Clinical Investigational Site 1024
🇺🇸Maitland, Florida, United States
Santarus Clinical Investigational Site 1031
🇺🇸New York, New York, United States
Santarus Clinical Investigational Site 1073
🇺🇸Wilmington, North Carolina, United States
Santarus Clinical Investigational Site 1080
🇺🇸Cincinnati, Ohio, United States
Santarus Clinical Investigational Site 1064
🇺🇸Lancaster, Pennsylvania, United States
Santarus Clinical Investigational Site 1005
🇺🇸Pasadena, Texas, United States
Santarus Clinical Investigational Site 1039
🇺🇸Houston, Texas, United States
Santarus Clinical Investigational Site 1014
🇺🇸Lancaster, Utah, United States
Santarus Clinical Investigational Site 1025
🇺🇸Christiansburg, Virginia, United States
Santarus Clinical Investigational Site 4004
🇧🇬Plovdiv, Bulgaria
Santarus Clinical Investigational Site 4008
🇧🇬Ruse, Bulgaria
Santarus Clinical Investigational Site 9008
🇷🇺Saint Petersburg, Russian Federation
Santarus Clinical Investigational Site 1021
🇺🇸Cheektowaga, New York, United States
Santarus Clinical Investigational Site 9017
🇷🇺Volgograd, Russian Federation
Santarus Clinical Investigational Site 1028
🇺🇸Bristol, Connecticut, United States
Santarus Clinical Investigational Site 2009
🇨🇦Montreal, Quebec, Canada
Santarus Clinical Investigational Site 2008
🇨🇦Halifax, Nova Scotia, Canada
Santarus Clinical Investigational Site 2001
🇨🇦Sherbrooke, Quebec, Canada